Hemoglobin Modulator Dosing for Sickle Cell Polymerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease do not effectively manage the polymerization of sickle hemoglobin (HbS) under hypoxic conditions, leading to rigid red blood cells and potential vessel blockages.
Innovation Solution
Administration of Compound I, (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde, or its pharmaceutically acceptable salt, in specific dosing regimens to achieve 25% to 60% hemoglobin occupancy, thereby modulating hemoglobin and reducing sickling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used, then sickle cell disease is managed, but polymerization of HbS under hypoxic conditions is not effectively inhibited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of hemoglobin through the introduction of a specific compound (Compound I) that alters the conformational state of HbS. This compound changes the physical-chemical parameters of hemoglobin, preventing polymerization under hypoxic conditions while maintaining oxygen transport function, thereby resolving the contradiction between managing the disease and preventing harmful polymerization.
2Stability of the object's composition
If HbS polymerization is not inhibited, then red blood cells remain flexible, but vessel blockages occur due to rigid sickled cells
Solution Approach 1:
The patent converts the harmful effect of HbS polymerization into a beneficial state by using Compound I to maintain hemoglobin in an oxygenated conformation. This prevents the formation of rigid sickled cells that cause vessel blockages, while the compound itself is eliminated through metabolic processes, leaving no harmful residues. The harmful polymerization tendency is transformed into stable, flexible red blood cells.
3Reliability
If Compound I is administered at high doses to achieve maximum hemoglobin occupancy, then sickling is reduced, but safety and tolerability may be compromised
Solution Approach 1:
The patent applies parameter changes by optimizing the dosing regimen to achieve a specific hemoglobin occupancy range (25-60%) rather than maximum occupancy. This optimized parameter range balances the therapeutic effect of reducing sickling with safety and tolerability, avoiding the harmful effects of excessive dosing while maintaining sufficient protection against polymerization.
Solution Approach 2:
The patent applies partial action by administering Compound I at doses that provide 25-60% hemoglobin occupancy rather than complete or excessive occupancy. This partial action is sufficient to prevent polymerization and reduce sickling events while avoiding the safety issues associated with high-dose administration, thus resolving the contradiction between therapeutic efficacy and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method achieves targeted hemoglobin occupancy, improving clinical outcomes for individuals with sickle cell disease by reducing vaso-occlusive crises and maintaining HbS in an oxygenated state.
Implementation Method 1
the administrations of the first dose and the second dose provide about 25% to about 60% hemoglobin occupancy of Compound I
Data Source
AI summary
Provided herein are methods for treating sickle cell disease comprising administering Compound (I), a modulator of hemoglobin, according to certain dosing regimens.